11 results about "Arrhythmic risk" patented technology

This invention discloses an online ECG control method and device for a pacemaker, relating to the field of medical device technology. The method includes: synchronously acquiring raw ECG and transient impedance signals; establishing an artifact waveform model based on impedance attenuation characteristics; removing pacing pulse artifacts; reconstructing a clean ECG signal and marking the capture state; extracting signal waveform features to construct a time-series matrix; inputting it into a pre-trained time-series prediction model to obtain future heart rate trajectories and arrhythmia risk probabilities; constructing a cost function including physiological comfort, safety penalties, and energy efficiency indicators; solving for the optimal pacing parameter vector using the gradient projection method; and driving the pacing circuit to output pulses. This invention effectively solves the artifact interference problem, achieving precise adaptive pacing control based on risk prediction and multi-objective optimization, significantly improving treatment safety and patient comfort.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The Cardiac Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

A non-invasive method for cardiac arrhythmia risk stratification may include identifying, based at least on an electrical recording of a patient, a cardiac depolarization simulation and a cardiac repolarization simulation corresponding to an electrical recording of a patient. One or more regions of increased spatial repolarization gradient in which a first area of a myocardium of the patient exhibits a first repolarization rate that differs from a second repolarization rate of a second area of the myocardium by an amount then divided by the spatial distance between the two regions, by a threshold value may be determined based on the cardiac depolarization simulation and the cardiac repolarization simulation. A risk of cardiac arrhythmia for the patient may be determined based a magnitude of the increased spatial repolarization gradient. Moreover, a treatment plan for the patient may be determined based on the magnitude and / or location of the increased spatial repolarization gradient.

A method for anesthetizing and / or sedating a subject with shorter QT interval or reduced risk of TdP or lower risk of cardiac arrhythmias, said method comprising administering an effective dose of cipepofol to the subject.

The Cardiac Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

A data-processing apparatus for deriving a parameter value indicative of a subject's risk of a future arrhythmia comprises a processing system (6), configured to, for a plurality of frames (500) of a sequence of two-dimensional magnetic field data frames, each representing the rate of change of a magnetic field in the subject's heart at a respective cardiac-cycle instant within a cardiac cycle, define a vector (510) extending between a minimum-rate-of-change position and a maximum-rate-of-change position. The system (6) is further configured to calculate a frame-pair angle change for a plurality of successive pairs of frames, by calculating the absolute value of the difference in angle (512) of the vector defined for each frame of the pair, and calculate the parameter value by taking a combination of at least two of the frame-pair angle changes.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of decreasing arrythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of treating arrythmia in a patient having, or at risk of having, arrythmia generally includes administering to the patient an miR-448 inhibitor in an amount effective to decrease the likelihood or extent of arrythmia in the patient. In some embodiments of all methods, the miR-448 inhibitor can be an miR-448 antagomir or an miR-448 sponge.

The invention concerns a computer-implemented method for the estimation of a risk of heart rhythm disorder in a patient's heart, the method comprising: (S03) receiving a mapping of points (IH) representing a tissue of said heart and each being labelled with a value (Ti) and / or a classification (Ci) indicating a local characteristic; (S2) simulating the propagation of electric signals from inducing locations (ILj), to which is applied virtual induction protocol (IPk); (S3) detecting from each simulation outcome (EAMj,k) whether a self-sustained arrhythmia is induced; (S5) a step of clustering, from simulation outcomes (EAMj,k), inducible sites into groups (GI) of similar inducible sites; (S6) a step of computing, for each group (GI) of similar inducible sites (ILj) and from the number (N) of inducible sites of said group, a risk value (RVI) indicating whether a heart rhythm disorder can occur.